FDA’s settlement of the Vascepa (icosapent ethyl) off-label marketing case is another important development in pharmaceutical and medical device industry First Amendment disputes that experts say may put additional pressure on FDA to revise its approach to off-label promotion.
The settlement with drug manufacturer Amarin Corp
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?